GLP-1 treatment to slow small blood-vessel brain damage
Part of Brain & nervous system, Heart & circulation clinical trials.
This Phase 2 study tests whether a GLP-1–like medicine can slow worsening “small vessel” disease changes in the brain and related walking and thinking problems. It aims to see if the treatment can prevent progression in people who already show early brain changes on MRI.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are Chinese and between 55 and 80 years old
- Your brain MRI shows early small-vessel–type white-matter changes (not from other rare diseases)
- You can walk at least limited distances and score enough on a walking assessment
- Your thinking test (MoCA) is below 25 but not in a dementia range
- You can safely take a GLP-1–type medicine (no related thyroid/pancreas/eye allergy issues)
- You can complete MRI scans safely (kidney function and implants/metal are compatible)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses brain scans (EEG and fMRI) to understand how small vessel disease affects walking. It may help find better ways to treat gait problems like slowness or imbalance.
This study tests a drug that targets a protein called TSPO to see if it can improve the function of the cells lining the small blood vessels in the brain of people with cerebral small vessel disease. It may help with mild memory or thinking problems.
This study tracks people with cerebral small vessel disease (CSVD) over time using MRI scans. It aims to understand how the condition changes and affects health, which could help improve future care.
This trial looks at how to slow cognitive decline and early dementia in people with a specific kind of “silent” blood vessel damage in the brain seen on scans. It may help identify whether targeting this hidden condition can protect thinking and memory over time.
This study tests a medicine (a GLP-1 receptor agonist) given along with the standard clot-removal procedure for people who have had a severe stroke from a large blockage. The goal is to see if the medicine helps improve recovery by protecting the brain.
This study tests whether a new medicine can improve blood vessel and insulin function in the brain while you continue your current Alzheimer's drug (lecanemab or donanemab). It may help the anti-amyloid therapy work better and slow down memory loss.
Hear when a new Cerebral Small Vessel Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.